Previous Close | 1.0900 |
Open | 1.1000 |
Bid | 1.0200 x 1800 |
Ask | 1.0900 x 1400 |
Day's Range | 1.0200 - 1.1100 |
52 Week Range | 1.0100 - 2.0300 |
Volume | |
Avg. Volume | 73,682 |
Market Cap | 39.469M |
Beta (5Y Monthly) | 0.89 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.9900 |
Earnings Date | Nov 08, 2023 - Nov 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for BOLT
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced today the issuance of the first and foundational patent covering BDC-3042. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 11,753,474 titled “Anti-Dectin-2 Antibodies,” on September 12, 2023. “The issuance of this patent is an important milestone in protecting the comp
REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September: Morgan Stanley 21st Annual Global Healthcare Conference Fireside chat on Tuesday, Sept. 12, at 3:35 p.m. EDT (12:35 p.m. PDT) H.C. Wainwright 25th Annual Global Investment Conference Management will be availabl
Bolt Biotherapeutics ( NASDAQ:BOLT ) Second Quarter 2023 Results Key Financial Results Net loss: US$18.1m (loss...